Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 16,299 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Double Blind Placebo Clear all
Completed Phase 2Phase 3 Interventional

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

NCT01741194
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AC-1204, Placebo
Drug
Lead sponsor
Cerecin
Industry
Eligibility
66 Years to 90 Years
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
82
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

NCT02720094
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Oral Tablet, TDF/FTC tablets, Placebo for TDF/FTC tablets, Placebo for cabotegravir oral tablet, CAB LA, Placebo for CAB LA
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4,570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 2 Interventional

Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

NCT01748877
View directory record Official record
Conditions
Post Herpetic Neuralgia
Interventions
NXN-462, Placebo
Drug
Lead sponsor
NeurAxon Inc.
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 3 Interventional Results available

TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)

NCT00387881
View directory record Official record
Conditions
Migraine, Without Aura
Interventions
sumatriptan succinate / naproxen sodium, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
70
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 58 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection

NCT02532283
View directory record Official record
Conditions
Influenza A Virus
Interventions
JNJ-63623872, Placebo, Oseltamivir
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Fresno, California • Long Beach, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 23, 2026, 8:22 AM EDT
Terminated Phase 3 Interventional Results available

Daptomycin Versus Placebo in Patients With Neutropenia and Fever

NCT01216241
View directory record Official record
Conditions
Febrile Neutropenia
Interventions
Daptomycin, Saline Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 2 Interventional Results available

A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy

NCT01006122
View directory record Official record
Conditions
Excessive Daytime Sleepiness, Narcolepsy
Interventions
Placebo, PF-03654746
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 23, 2026, 8:22 AM EDT
Terminated Phase 2 Interventional Results available

Pregabalin for the Treatment of Vulvodynia

NCT00853229
View directory record Official record
Conditions
Vulvodynia, Vulvar Vestibulitis
Interventions
pregabalin
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Botulinum Toxin is a Potential Prophylactic Therapy for Minimizing Post-excisional Scarring (Allergan Botox Scar Study)

NCT02623829
View directory record Official record
Conditions
Post-operative Excessive Scarring
Interventions
Botulinum Toxin, Saline
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome

NCT01545037
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®, Placebo
Dietary Supplement · Other
Lead sponsor
Bio-K Plus International Inc.
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
3
States / cities
Garden Grove, California • San Francisco, California • Westlake Village, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder

NCT01052077
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
OPC-34712, Placebo, ADT
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
43
States / cities
Birmingham, Alabama • Arcadia, California • Beverly Hills, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 3 Interventional

Hymovis™ Versus Placebo in Knee Osteoarthritis

NCT01372475
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Hymovis Intra-articular Injection, Phosphate Buffered Saline Injection
Device · Procedure
Lead sponsor
Fidia Farmaceutici s.p.a.
Industry
Eligibility
40 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Birmingham, Alabama • Tucson, Arizona • Encinitas, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Preoperative N1539 in Total Knee Arthroplasty

NCT03434275
View directory record Official record
Conditions
Pain, Postoperative
Interventions
N1539, Placebo
Drug
Lead sponsor
Baudax Bio
Industry
Eligibility
35 Years to 80 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Florence, Alabama • Mobile, Alabama • Sheffield, Alabama + 3 more
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study in Participants With Moderate to Severe Psoriasis

NCT01474512
View directory record Official record
Conditions
Psoriasis
Interventions
80 mg Ixekizumab Dosing Regimens 1, 2, and 3, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
34
States / cities
Birmingham, Alabama • Anaheim, California • Bakersfield, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Oct 23, 2026, 8:22 AM EDT
Terminated Not applicable Interventional

To Evaluate SBI in the Dietary Management of Mild to Moderate Crohn's Disease

NCT02649075
View directory record Official record
Conditions
Crohn's Disease
Interventions
Serum-derived Bovine Immunoglobulin / Protein Isolate, Placebo
Other
Lead sponsor
Entera Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
North Little Rock, Arkansas • Hollywood, Florida • Winter Park, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 3 Interventional

Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation

NCT01674530
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
909 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
93
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 71 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 2 Interventional

CS02 vs Placebo With Metformin in Type 2 Diabetes Mellitus (T2DM)

NCT03317028
View directory record Official record
Conditions
T2DM With Inadequate Glycemic Control
Interventions
CS02 tablet and placebo tablet
Drug
Lead sponsor
Center Laboratories, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Little Rock, Arkansas • Coral Gables, Florida • Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients

NCT02802228
View directory record Official record
Conditions
Portal Hypertension, Liver Cirrhosis
Interventions
Ifetroban, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Tampa, Florida • Indianapolis, Indiana • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 3 Interventional Results available

Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy

NCT02355665
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Nicotine Spray, Placebo
Drug
Lead sponsor
McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Scottsdale, Arizona • Burbank, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 2 Interventional Results available

A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins

NCT02634151
View directory record Official record
Conditions
Hypercholesteremia
Interventions
Gemcabene, Placebo
Drug
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
24
States / cities
Birmingham, Alabama • Beverly Hills, California • Huntington Park, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model

NCT03284931
View directory record Official record
Conditions
Healthy
Interventions
SAGE-217 high dose, Placebo, SAGE-217 low dose
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 64 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 23, 2026, 8:22 AM EDT
Recruiting Phase 2 Interventional

A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.

NCT07215702
View directory record Official record
Conditions
Sepsis, Acute Kidney Injury
Interventions
AZD4144, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
16
States / cities
Phoenix, Arizona • Newport Beach, California • Kansas City, Kansas + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 4 Interventional Results available

Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF)

NCT02677701
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
azithromycin, placebo (for azithromycin), inhaled tobramycin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
12 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
39
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 3 Interventional Results available

A Physical Dependence Study in Schizophrenia

NCT01452919
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, Placebo
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
8
States / cities
Oakland, California • San Diego, California • Torrance, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 23, 2026, 8:22 AM EDT